Dermatomyositis patients with anti-TIF1ꝩ autoantibodies have a particularly high risk of malignancy [4, 30, 31], while those with anti-NXP2 autoantibodies have a significant but lower risk [5]. This evidence concerns the gene MORC3 and dermatomyositis.